Ernexa Therapeutics completes manufacturing milestones for ERNA-101 May 27, 2026 08:11AM
Brookline Capital Markets Starts Ernexa Therapeutics (ERNA) at Buy May 7, 2026 03:23PM
Ernexa Therapeutics reports complete tumor elimination in ovarian cancer study May 6, 2026 08:33AM
Ernexa Therapeutics plans first-in-human trials for cancer therapy Mar 31, 2026 08:55AM
Eterna Therapeutics (ERNA) files $50M mixed shelf Mar 16, 2026 06:07AM


Feb 3, 2026 06:09AM Eterna Therapeutics (ERNA) files for proposed share and warrant offering
Jan 27, 2026 08:45AM Ernexa Therapeutics selected for JETRO Japan acceleration program
Jan 6, 2026 08:15AM Ernexa Therapeutics receives FDA alignment for ovarian cancer trial
Dec 8, 2025 08:32AM Ernexa presents preclinical data on ovarian cancer cell therapy at ASH
Oct 29, 2025 08:33AM Cellipont partners with Ernexa to manufacture ERNA-101 cancer therapy
Sep 10, 2025 08:30AM Ernexa Therapeutics cuts operating loss by 51% in first half of 2025
Jul 9, 2025 08:30AM Ernexa Therapeutics regains Nasdaq compliance with minimum bid price rule
Jun 24, 2025 08:32AM Eterna Therapeutics (ERNA) Secures $6M in Second Closing Under Securities Purchase Agreement
Jun 11, 2025 04:36PM Ernexa Therapeutics (ERNA) Files for 57.05M Share Offering by Selling Stockholders
Jun 10, 2025 09:30AM Eterna Therapeutics (ERNA) Announces 1:15 Reverse Share Split
May 8, 2025 08:30AM Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
Apr 29, 2025 08:33AM Ernexa Therapeutics (ERNA) Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
Mar 25, 2025 08:31AM Eterna Therapeutics (ERNA) changes name to Ernexa Therapeutics
Jan 28, 2025 08:31AM Eterna Therapeutics (ERNA) Expands Scientific Advisory Board
Jan 14, 2025 08:34AM Eterna Therapeutics (ERNA) Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
Dec 3, 2024 08:33AM Eterna Therapeutics (ERNA) Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and
Nov 25, 2024 08:30AM Eterna Therapeutics (ERNA) Announces $1M Share Buyback
Nov 14, 2024 08:34AM Eterna Therapeutics (ERNA) Regains Compliance with NASDAQ for Continued Listing
Nov 5, 2024 04:33PM Eterna Therapeutics (ERNA) Files for 49.87M Share Offering by Selling Stockholders
Oct 17, 2024 08:01AM Eterna Therapeutics (ERNA) and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases